Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

se of this study is to assess the efficacy and safety of lower doses of quizartinib in the treatment of patients 18-years or older with relapsed/refractory FLT3 ITD positive AML to further improve the benefit:risk assessment of quizartinib. The data will be presented by Dr. Jorge Cortes at 3:00 pm CT on Monday, December 9, in the La Nouvelle Ballroom C.

Quizartinib Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Experience From The AML Pilot Trial:  This is the first presentation of quizartinib use in combination with chemotherapy in newly diagnosed older AML patients, testing the feasibility and dose which could be given sequentially following conventional chemotherapy in patients over the age of 60 years.  The data will be presented by Dr. Alan Burnett at 5:15 pm CT on Monday, December 9, in the La Nouvelle Ballroom C.

Results of Phase 1 Study of Quizartinib In Combination with Induction and Consolidation Chemotherapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia:  This dose escalation study is the first to report data on quizartinib in combination with standard induction and consolidation chemotherapy in patients between the ages of 18 to 60-years with newly diagnosed AML, regardless of FLT3 status. The data will be presented by Dr. Jessica Altman at 5:30 pm CT on Monday, December 9, in the La Nouvelle Ballroom C.

A Phase I Study of Quizartinib in Combination with Cytarabine and Etoposide in Relapsed/Refractory Childhood ALL and AML:  A Therapeutic Advances in Childhood Leukemia & Lymphoma Study:  This was the first clinical trial using quizartinib in children between the ages of 1 month and 21-years with relapsed/refractory AML or MLL-rearranged ALL.  The data will be presented by Dr. Todd Coope
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... March 02, 2015 Global ... formed alliance with Shenzhen HANK Bioengineering Co., Ltd. ... The alliance will establish a stem cells training ... China in September 2015. , Shenzhen HANK is ... an award-winning scientist, microbiologist and virologist, to integrate ...
(Date:3/1/2015)... 2015 Market Publishers Ltd and ... market research promotion on Internet. MarketPublishers.com is now ... out by DataGroup Booksellers. , Natalie Aster, Assistant ... commented on the recent partnership agreement as follows: ... our team of publishers. Since 1974, the company ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Immunovaccine Inc. ... aware of a fraudulent press release disseminated this morning ... be from Immunovaccine. This press release states that Immunovaccine ... Inc. The press release did not originate from ... contained within the press release. Please note that ...
(Date:2/27/2015)...  Pharmacyclics, Inc. (NASDAQ: PCYC ) ... newly developed Bruton,s tyrosine kinase (BTK) inhibitor for ... results of these preclinical evaluations have been communicated ... feedback received from the Agency is supportive of ... preclinical work is required to begin a Phase ...
Breaking Biology Technology:Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 2Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 3Immunovaccine Disclaims Hoax Press Release 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3
... ... , ... (PRWEB) June 16, 2010 -- The American Medical Writers Association named medical writer, Rita ... Solimene Awards for Excellence in Medical Communication. She received the awards for The Lehman ...
... Germany , June 16, 2010 ,The medical devices company joimax(R) GmbH is ... had already been the motto of,the last company move back in 2005. , ... The US market has an enormous ... to Irvine, California , one,of high-tech industry centers in the United States ...
... is dramatically expanding the ability of researchers to ... internal structures. And recent advances in X-ray diffraction ... approach. While significant progress has ... diffraction barrier, such techniques rely on fluorescent labeling ...
Cached Biology Technology:Medical Writer Rita Buckley Wins Awards for Excellence in Medical Communication 2Medical Writer Rita Buckley Wins Awards for Excellence in Medical Communication 3joimax(R) Moves Into Larger Premises 2Researchers use X-ray diffraction microscope to reveal 3-D internal structure of whole cell 2Researchers use X-ray diffraction microscope to reveal 3-D internal structure of whole cell 3
(Date:2/5/2015)... VIEW, Calif. , Feb. 3, 2015 /PRNewswire/ ... printer technology, demand from industries such as consumer ... global market for surface mount technology (SMT) screen ... equipment to automatic control will push the adoption ... dispensers will remain steady as glue dispensers are ...
(Date:1/22/2015)... DETROIT , Jan. 13, 2015 Technology Showcase, Hall ... iris-based identity authentication solutions, today announced it will showcase its ... and developed by the Department of Energy,s Oak Ridge ... International Auto Show . EyeLock,s iris identity authentication technology is ...
(Date:1/22/2015)... Jan. 21, 2015  Analyst Report Issued by Small Cap IR. ... showed that planet-wide, transactions at merchants on the leading payment ... number of credit, debit, and prepaid cards reached 6.54 billion.  ... of fraudulent card usage in 2012, and credit and debit ...
Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... Elsevier, a world-leading provider of scientific, technical and ... it received six 2012 PROSE Awards and three ... the American Publishers Awards for Professional and ... of American Publishers, Professional and Scholarly Publishing Division ...
... to an extraordinary diversity of insect species. How great is ... the Santa Barbara Museum of Natural History published ... towards an answer to this question. The paper was published ... . Entomologists Michael Caterino and Alexey Tishechkin have named ...
... worldwide, and aHUS, a rare kidney disease that affects ... protein called complement factor H (CFH) is responsible for ... cascade. Genetic alterations in CFH have been shown to ... aHUS, but rarely both. Why this is the case ...
Cached Biology News:Elsevier wins 6 PROSE Awards 2Little did we know about beetle diversity: Astonishing 138 new species in a single genus 2Molecular basis identified for tissue specific immune regulation in the eye and kidney 2Molecular basis identified for tissue specific immune regulation in the eye and kidney 3
... of Class II Biological Safety Cabinets ... to the world's highest safety standards. ... cabinets cannot be adjusted out of ... noise and arm rest ensure safety ...
... Thermo has recently launched a custom ... RNA (siRNA). Thermos siRNA molecules are: ... with 2 DNA bases overhang at ... Delivered fully deprotected and ready-to-use. ...
... Thermo's orbital shaker stands both ... more ergonomic height, and help ... from welded tubular steel, these ... support the weight and minimize ...
Mouse monoclonal [AZ24] to Polo like kinase ( Abpromise for all tested applications)....
Biology Products: